

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 18, 2017

**POSITIVEID CORPORATION**

(Exact name of registrant as specified in its charter)

---

**Delaware**

(State or Other Jurisdiction  
of Incorporation)

---

**001-33297**

(Commission  
File Number)

---

**06-1637809**

(IRS Employer  
Identification Number)

**1690 South Congress Avenue, Suite 201  
Delray Beach, Florida 33445**  
(Address of principal executive offices) (zip code)

**(561) 805-8000**  
(Registrant's telephone number, including area code)

---

(Former Name or Former Address if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

### **Cautionary Note on Forward-Looking Statements**

This Current Report on Form 8-K (this “Report”) and any related statements of representatives and partners of the Company contain, or may contain, among other things, certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission (the “SEC”). Actual results may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

### **Item 8.01 Other Events.**

On September 18, 2017, PositiveID Corporation (the “Company”) determined it needed to reschedule its previously scheduled press conference announcing the history of the FireflyDX product, advancements in the Company’s technology, and the Lawrence Livermore National Laboratory (“LLNL”) report prepared for the Company’s ExcitePCR Corporation subsidiary on its FireflyDX technology. While the Company has received the final report from LLNL, it is still in discussions with LLNL on the appropriate terms of publication and dissemination of the report. The Company had expected to complete this process by September 15th. It now hopes to complete this process by October 2017.

The panel discussion featuring the Company’s President, Lyle L. Probst, to be held today, September 18th, hosted by the National Academies of Science, Engineering, and Medicine (NAS) will commence at 3:30 pm ET. The panel discussion is part of a two-day, BioWatch Workshop on “Strategies for Effective Biological Detection Systems” hosted by the NAS, and will cover current and future advancements in pathogen detection systems.

---

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**POSITIVEID CORPORATION**

Date: September 18, 2017

By: /s/ William J. Caragol

Name: William J. Caragol

Title: Chief Executive Officer

---

